17.03.2015 • News

Sharon Johnson to Head Catalent’s Quality, Product Development & Regulatory Affairs

Sharon Johnson is to head Catalent's newly formed Quality, Product Development & Regulatory Affairs organization. In her new role she will oversee a global function that includes more than 1,500 scientists, quality professionals and regulatory affairs experts.

Prior to assuming her new responsibilities, Johnson had served as Catalent's Senior Vice President, Global Quality & Regulatory Affairs since 2009. She has more than thirty years of experience in the pharmaceutical industry, including API and multiple dosages forms, from discovery and launch of NCEs and life cycle management. Before joining Catalent, Johnson served as Vice President of Quality for GE Healthcare's Medical Diagnostic Division, having previously worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.

Johnson holds a postgraduate Diploma in Industrial Pharmaceutical Studies with Distinction from Brighton University and a BS Honours degree in Biological Sciences/Microbiology from North East Surrey College of Technology.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.